Denial of Amgen injunction in Regeneron patent row affirmed by US appeals court
MLex Summary: The US Court of Appeals for the Federal Circuit that Regeneron is not likely to succeed on the merits in its patent infringement action against Amgen Pharmaceuticals, which alleges...To view the full article, register now.
Already a subscriber? Click here to view full article